대동맥류 시장 : 대동맥류 유형, 치료법, 기기 유형 유형, 적응증, 환자 연령층, 성별, 최종 사용자별 - 세계 예측(2026-2032년)

The Aortic Aneurysm Market was valued at USD 5.22 billion in 2025 and is projected to grow to USD 5.69 billion in 2026, with a CAGR of 9.14%, reaching USD 9.63 billion by 2032.

An overarching introduction that frames the evolving clinical, technological, and delivery dynamics shaping aortic aneurysm treatment and stakeholder decision-making

Aortic aneurysm management sits at the intersection of surgical innovation, demographic shifts, and evolving healthcare delivery models. Recent years have seen the steady migration of clinical preference toward less invasive therapies, concurrent advances in imaging and device technology, and a heightened emphasis on perioperative risk mitigation. These dynamics converge against a backdrop of an ageing population with rising cardiovascular comorbidity burden, creating sustained clinical demand while simultaneously intensifying the focus on safety, long-term durability, and cost-effective pathways for intervention.

Clinicians and health system leaders are now navigating a more complex therapeutic landscape in which endovascular options must be balanced against open repair approaches based on anatomical suitability, patient frailty, and access-to-care considerations. Device designers are responding with increasingly sophisticated stent graft architectures, refined delivery systems, and adjunctive tools to address challenging anatomies such as short-necked infrarenal aneurysms and complex thoracoabdominal lesions. At the same time, payors and hospital administrators are scrutinizing procedural site selection and resource utilization, prompting closer evaluation of ambulatory surgery centers and streamlined care protocols.

This executive summary synthesizes current clinical trends, regulatory and commercial shifts, and provider-level strategic implications to support clinicians, manufacturers, and investors in making informed decisions. The analysis emphasizes actionable insights into modality choice, device differentiation, end-user adoption patterns, and regional variations that are shaping the path forward for aortic aneurysm care.

An in-depth analysis of how clinical innovation, care setting transitions, and regulatory emphasis are reshaping aortic aneurysm treatment paradigms across stakeholders

The landscape of aortic aneurysm care is undergoing transformative shifts driven by technological maturation, changing care settings, and the reframing of value across stakeholders. Minimally invasive endovascular repair has progressed from a niche alternative to a default option for many anatomies, supported by improved imaging fidelity, navigation systems, and modular stent graft designs that address previously inoperable segments. These advances are complemented by perioperative optimization techniques and enhanced recovery protocols that reduce length of stay and procedural morbidity, thereby altering the calculus of clinical decision-making.

Concurrently, device innovation is moving toward personalized solutions, including fenestrated and branched endografts, low-profile delivery systems, and materials engineered for long-term durability and reduced thrombogenicity. These innovations expand candidacy for endovascular approaches, particularly among older or comorbid patients who would face higher risks with open surgical repair. The shift is not purely technological; it reflects an ecosystem change where multidisciplinary teams, including vascular surgery, interventional radiology, and cardiac surgery, increasingly collaborate to tailor therapy to patient-specific anatomy and risk profiles.

Health systems are also redefining care pathways, directing lower-risk elective procedures to ambulatory settings and employing telemedicine and remote monitoring for follow-up surveillance. This decentralization of care pressures device manufacturers to standardize training, simplify deployment, and ensure consistent outcomes across disparate settings. Lastly, regulatory emphasis on post-market surveillance and real-world evidence is prompting companies to invest in registries and longitudinal studies, which in turn inform clinical guidelines and payer coverage policies. Together, these shifts create both opportunity and competitive pressure for stakeholders to adapt strategy, investment, and product development roadmaps.

A detailed exploration of how the 2025 United States tariff changes have influenced device sourcing, manufacturing strategies, and procurement decisions across the aortic aneurysm ecosystem

Tariff adjustments implemented in the United States in 2025 introduced a new variable into the supply chain calculus for medical device manufacturers, health systems, and distributors involved in aortic aneurysm care. Many devices and components used in endovascular and open surgical repairs are sourced globally, and changes in import duties can result in increased landed costs for stent grafts, synthetic conduits, and ancillary delivery components. These cost pressures ripple through procurement processes, prompting hospital supply chain teams to renegotiate contracts, reassess supplier diversification strategies, and evaluate the feasibility of localizing certain manufacturing or sterilization processes.

The cumulative impact of the tariff measures has prompted manufacturers to reassess their global sourcing footprints, with some prioritizing regional production hubs to mitigate exposure to trade fluctuations. For devices that rely on specialized raw materials or implants produced by a limited set of suppliers, tariffs have amplified the need for transparent cost structures and contingency planning. Health systems facing constrained operating budgets may respond by enhancing value-based contracting, extending device reuse policies within regulatory allowances, or prioritizing procedural modalities that demonstrate stronger cost-effectiveness in their local contexts.

Regulatory and reimbursement bodies have also taken notice, and the interplay between import duties and pricing has the potential to alter negotiations around bundled payments and procedural reimbursement. For international suppliers, tariff-induced pricing changes may slow market entry or shift commercialization timelines, particularly for high-complexity devices that require substantial clinical evidence prior to adoption. Ultimately, the 2025 tariff environment underscores the importance of supply-chain resilience, flexible manufacturing strategies, and closer collaboration between manufacturers and providers to preserve access to life-saving aortic aneurysm interventions while managing economic impacts.

Segment-driven insights that connect treatment modalities, anatomical complexity, care settings, and patient demographics to actionable clinical and commercial strategies

Segmentation analysis reveals distinct clinical pathways and commercial considerations that influence treatment selection, device demand, and provider adoption. Based on treatment modality, clinicians weigh endovascular repair against open surgical repair by considering patient anatomy and physiological resilience; endovascular techniques increasingly leverage stent graft systems with advanced delivery platforms to expand applicability, while open surgical repair continues to rely on both biological conduits and synthetic vascular grafts where durability and specific anatomical requirements dictate approach.

When viewed through the lens of aneurysm type, abdominal aortic aneurysms and thoracic aortic aneurysms present different technical challenges and device requirements. Abdominal presentations are further stratified by infrarenal, juxtarenal, and suprarenal locations, each demanding unique fixation and sealing strategies, whereas thoracic presentations span ascending, descending, and thoracoabdominal segments that often require branched or fenestrated designs to preserve branch vessel integrity. These anatomical distinctions drive product development priorities, imaging protocols, and operator training needs.

End-user segmentation highlights divergent adoption curves and procedural settings. Ambulatory surgery centers, including cardiology-centered facilities and standalone surgery centers, are increasingly attractive for lower-risk, elective interventions that benefit from streamlined throughput and lower overhead. Conversely, hospitals, whether general, specialized vascular centers, or tertiary care institutions, maintain primacy for high-complexity cases and ruptured presentations that require multidisciplinary resources and critical care capabilities.

Device type segmentation isolates stent graft systems and synthetic vascular grafts as core product categories, each with unique regulatory pathways, sterilization requirements, and surgeon preferences. Indication-based segmentation differentiates elective repairs, where optimization of recovery and cost containment are priorities, from rupture repairs, which demand immediate access to robust devices and emergent care pathways. Patient demographics further nuance demand patterns, with an older cohort driving higher procedural volume and anatomical complexity; gender differences shape risk stratification and anatomical fit considerations, necessitating inclusive design and evidence generation across populations.

A regional assessment highlighting how divergent healthcare infrastructures, reimbursement approaches, and clinical practices shape aortic aneurysm care across major global geographies

Regional dynamics produce meaningful variation in clinical practice, infrastructure readiness, and regulatory expectations that affect how aortic aneurysm care is delivered and how products are commercialized. In the Americas, there is a strong emphasis on minimally invasive approaches coupled with robust private and public payer systems; advanced imaging networks and high-volume tertiary centers support rapid adoption of novel endografts and complex fenestrated solutions, while ambulatory settings are progressively absorbing lower-risk elective cases.

Europe, Middle East & Africa present a heterogeneous landscape where western European markets emphasize guideline-driven adoption and centralized specialized vascular centers, and emerging markets across the Middle East and Africa grapple with infrastructure constraints and variable access to advanced devices. Regulatory alignment with regional authorities and investments in training and centers of excellence are critical to expanding reach across these diverse healthcare systems.

Asia-Pacific demonstrates accelerated uptake in innovation in several urbanized markets that combine high procedure volumes with expanding ambulatory infrastructures. Local manufacturing capacities and partnerships with global manufacturers are shaping access and price dynamics, while demographic trends and public health initiatives are increasing screening and early detection efforts. Across regions, differences in reimbursement structures, clinical guideline adoption, and workforce availability create distinct strategic imperatives for manufacturers and providers seeking sustainable growth and clinical impact.

An industry-focused overview of how innovation pipelines, supply chain agility, and evidence generation are shaping competitive differentiation among device manufacturers

Corporate strategy in the aortic aneurysm domain centers on sustained innovation, clinical evidence generation, and operational scale. Leading device developers prioritize investments in next-generation stent graft architectures, low-profile delivery systems, and materials science to improve long-term outcomes and broaden anatomical applicability. Strategic alliances between device innovators and contract manufacturers or imaging technology firms are increasingly common, enabling integrated solutions that combine implant performance with advanced navigation and intraoperative imaging.

Investment in post-market surveillance and real-world data initiatives has become a differentiator, supporting regulatory submissions, payer negotiations, and clinician confidence. Firms that can demonstrate comprehensive training programs, robust customer support, and streamlined logistics achieve higher penetration across ambulatory and hospital settings. Meanwhile, smaller and emerging medtech companies focus on niche innovations-such as branched configurations for complex thoracoabdominal repairs or biologically optimized graft materials-positioning themselves for acquisition or strategic partnerships with larger players.

Supply-chain agility and regional manufacturing presence influence competitive positioning, particularly in areas affected by trade policy shifts. Companies that proactively localize production or diversify supplier networks reduce exposure to tariff volatility and distribution bottlenecks. Additionally, those that invest in digital tools for follow-up surveillance, patient-reported outcomes, and remote monitoring create differentiated value propositions for health systems prioritizing longitudinal care and cost containment.

Actionable strategic recommendations that align product development, supply chain resilience, and value-based commercialization to accelerate adoption and clinical impact

Industry leaders should adopt a multi-pronged strategy that aligns product innovation with care delivery trends, regulatory expectations, and procurement realities. First, prioritize modular and anatomically adaptable device platforms that reduce procedure complexity and expand the pool of patients eligible for less invasive treatment, thereby enabling broader adoption across diverse care settings. Second, invest in robust real-world evidence generation and registries to accelerate payer acceptance, validate long-term safety, and inform iterative product improvements that are grounded in clinical practice realities.

Third, strengthen supply-chain resilience by diversifying supplier bases, exploring regional production hubs, and developing contingency plans for component sourcing to mitigate the impact of trade policy shifts. Fourth, tailor commercial approaches to end-user segmentation by offering targeted training and support programs for ambulatory surgery centers, and by providing integrated clinical pathways for tertiary hospitals managing complex rupture cases. Fifth, collaborate with health systems to pilot bundled-care models and outcome-based contracts that align reimbursement with value delivered, thus improving access while demonstrating cost-effectiveness.

Finally, foster multidisciplinary clinician engagement and invest in education that promotes appropriate patient selection, surveillance protocols, and secondary prevention; this clinician-centric approach supports safer adoption of novel devices and strengthens long-term patient outcomes. These combined actions will position organizations to capture clinical and commercial opportunities while managing operational risks.

A transparent explanation of the blended qualitative and quantitative research approach used to derive clinical, commercial, and supply chain insights for aortic aneurysm care

The research methodology underpinning this executive summary integrates qualitative and quantitative approaches to ensure rigorous, evidence-based insights. Primary inputs include expert interviews with vascular surgeons, interventionalists, hospital procurement leaders, and device regulatory specialists to capture current clinical practice, device preferences, and adoption barriers. These clinician-level perspectives are supplemented by discussions with supply-chain and commercial leaders to understand manufacturing considerations, distribution dynamics, and the implications of recent trade policies.

Secondary research involved a systematic review of peer-reviewed clinical literature, regulatory guidance documents, and professional society position statements to validate clinical trends and device-specific performance characteristics. Where appropriate, registry data and published post-market surveillance reports were analyzed to assess safety signals and durability considerations, and findings were triangulated across multiple sources to enhance robustness. The segmentation framework was applied to map product types, indications, end-user settings, and patient cohorts to ensure that insights reflect the diversity of clinical pathways and commercial channels.

Finally, analytic rigor was maintained through cross-validation of thematic findings with independent experts and iterative refinement of conclusions to reflect both clinical nuance and commercial realism. This blended methodology supports actionable recommendations while acknowledging areas where evidence remains emergent and where ongoing surveillance will be required.

A concise conclusion summarizing the interplay of clinical innovation, supply chain dynamics, and strategic imperatives that will determine future success in aortic aneurysm care

Aortic aneurysm care is at an inflection point where technological innovation, demographic pressures, and changing care models intersect to create both opportunity and complexity for clinicians, manufacturers, and health systems. The move toward minimally invasive endovascular strategies is broadening treatment candidacy and shifting resource allocation, while device developers respond with targeted innovations that address anatomical challenges and long-term durability. At the same time, commercial and policy developments, including trade dynamics and payer scrutiny, are influencing procurement strategies and go-to-market approaches.

Stakeholders that align product development with clinical evidence, invest in training and post-market surveillance, and build resilient supply chains will be best positioned to deliver patient-centered outcomes while achieving sustainable commercial performance. Embracing collaborative models with health systems and payers that emphasize value and outcomes will further enable access to advanced therapies and support the long-term viability of innovative solutions. As the landscape continues to evolve, continued monitoring of clinical data, regulatory developments, and regional care models will be essential to refine strategies and maintain alignment with emerging best practices.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Aortic Aneurysm Market, by Aneurysm Type

• 8.1. Abdominal Aortic Aneurysm
  • 8.1.1. Infrarenal
  • 8.1.2. Juxtarenal
  • 8.1.3. Suprarenal
• 8.2. Thoracic Aortic Aneurysm
  • 8.2.1. Ascending
  • 8.2.2. Descending
  • 8.2.3. Thoracoabdominal

9. Aortic Aneurysm Market, by Treatment Modality

• 9.1. Endovascular Repair
• 9.2. Open Surgical Repair
  • 9.2.1. Biological Conduit
  • 9.2.2. Synthetic Vascular Graft

10. Aortic Aneurysm Market, by Device Type

• 10.1. Stent Graft
• 10.2. Synthetic Vascular Graft

11. Aortic Aneurysm Market, by Indication

• 11.1. Elective Repair
• 11.2. Rupture Repair

12. Aortic Aneurysm Market, by Patient Age Group

• 12.1. 65 And Above
• 12.2. Under 65

13. Aortic Aneurysm Market, by Gender

• 13.1. Female
• 13.2. Male

14. Aortic Aneurysm Market, by End User

• 14.1. Ambulatory Surgery Centers
  • 14.1.1. Cardiology Centers
  • 14.1.2. Standalone Surgery Centers
• 14.2. Hospitals
  • 14.2.1. General Hospitals
  • 14.2.2. Specialized Vascular Centers
  • 14.2.3. Tertiary Care Hospitals

15. Aortic Aneurysm Market, by Region

• 15.1. Americas
  • 15.1.1. North America
  • 15.1.2. Latin America
• 15.2. Europe, Middle East & Africa
  • 15.2.1. Europe
  • 15.2.2. Middle East
  • 15.2.3. Africa
• 15.3. Asia-Pacific

16. Aortic Aneurysm Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Aortic Aneurysm Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. United States Aortic Aneurysm Market

19. China Aortic Aneurysm Market

20. Competitive Landscape

• 20.1. Market Concentration Analysis, 2025
  • 20.1.1. Concentration Ratio (CR)
  • 20.1.2. Herfindahl Hirschman Index (HHI)
• 20.2. Recent Developments & Impact Analysis, 2025
• 20.3. Product Portfolio Analysis, 2025
• 20.4. Benchmarking Analysis, 2025
• 20.5. Abbott Laboratories
• 20.6. Altura Medical Inc.
• 20.7. Artivion, Inc.
• 20.8. Bentley InnoMed GmbH
• 20.9. Bolton Medical, Inc.
• 20.10. Boston Scientific Corporation
• 20.11. Cardinal Health company
• 20.12. Cook Medical Inc.
• 20.13. CryoLife, Inc.
• 20.14. Endologix Inc.
• 20.15. Johnson & Johnson Services, Inc.
• 20.16. Koninklijke Philips N.V.
• 20.17. Lemaitre Vascular Inc.
• 20.18. LifeTech Scientific Corporation
• 20.19. LivaNova PLC
• 20.20. Lombard Medical, Inc.
• 20.21. Medtronic PLC
• 20.22. MicroPort Scientific Corporation
• 20.23. Phenox GmbH
• 20.24. Terumo Corporation
• 20.25. W. L. Gore & Associates, Inc.